Don't get left behind! The modernized is coming. Check it out now.
Say goodbye to!
The new site is coming soon - go to the modernized
Working… Menu
Trial record 1 of 1 for:    CRLM-Z
Previous Study | Return to List | Next Study

Evaluation of Tumour Growth and Oncological Treatment in Patients With CRLM Using Zebra Fish Embryo Model (CRLM-Z)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT05289076
Recruitment Status : Not yet recruiting
First Posted : March 21, 2022
Last Update Posted : March 21, 2022
Medical Research Council of Southeast Sweden
Sahlgrenska University Hospital, Sweden
Information provided by (Responsible Party):
Per Sandström, University Hospital, Linkoeping

Brief Summary:
In order to improve and individualize cancer treatment, personalized treatment needs to be developed much further. Liver metastasizing colorectal cancer is treated with a combination of oncological and surgical interventions. The selection of chemotherapy is today mainly done according to best guess. Today only a small fraction of oncological treatment may be known to be effective in a person before treatment start, most often it is trial and error. A fast reliable system for looking at response to different treatments in each unique patient is much needed and would, if successful, completely change the way we give oncological treatment today. Patient's tumor tissue will be evaluated with use of zebrafish embryo avatars to evaluate tumour growth and response to different combinations of chemotherapy. If successful interventional studies are planned.

Condition or disease
Colorectal Cancer Metastatic Tumour Metastasis Chemotherapy Effect Tumor Growth

Show Show detailed description

Layout table for study information
Study Type : Observational
Estimated Enrollment : 40 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: Protocol for Evaluation of Oncological Treatment in Patients With CRLM Using Zebra Fish Avatars-may This Model Improve Resection Rates and Survival in Patients With Upfront Non-resectable Metastatic Disease?
Estimated Study Start Date : March 14, 2022
Estimated Primary Completion Date : March 14, 2024
Estimated Study Completion Date : March 14, 2025

Colorectal liver metastsis
Tumour tissue from patients operated for colorectal liver metastases. A cubic centimeter of tumour tissue will be processed and implanted in zebra fish embryos.

Primary Outcome Measures :
  1. Successful tumour growth in zebra fish embryos [ Time Frame: In each embryo within 3 days ]
    % of implanted tumour that grow in zebrafish embryos

  2. Response evaluation of different combinations of chemotherapy in zebra fish embryos implanted with colorectal liver metastatic tissue [ Time Frame: In each embryo within 3 days ]
    The relative tumour area between the time of implantation and day 3 in each zebrafish embryo

Biospecimen Retention:   Samples With DNA
colorectal liver metastasis

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Sampling Method:   Probability Sample
Study Population
Patients admitted for surgical resection of colorectal liver metastasis

Inclusion Criteria:

Confirmed or suspected diagnosis of colorectal liver metastasis Age 18 years or older ECOG 0-2 Patient can understand verbal and written information -

Exclusion Criteria:

Age less than 18 years ECOG >2 Patient is not able to understand the verbal and written information


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT05289076

Layout table for location contacts
Contact: Per Sandström, Prof +46734058581
Contact: Bergthor Bjornsson, Prof +46101033666

Layout table for location information
Per Sandström
Linköping, Ostergotland, Sweden, 58185
Sponsors and Collaborators
University Hospital, Linkoeping
Medical Research Council of Southeast Sweden
Sahlgrenska University Hospital, Sweden

Layout table for additonal information
Responsible Party: Per Sandström, Professor of surgery, University Hospital, Linkoeping Identifier: NCT05289076    
Other Study ID Numbers: Academic study
First Posted: March 21, 2022    Key Record Dates
Last Update Posted: March 21, 2022
Last Verified: March 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided
Plan Description: Anonymous data will be available

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Neoplasm Metastasis
Neoplastic Processes
Pathologic Processes